Catamaran Bio to Present Preclinical Efficacy Data for Allogeneic CAR‑NK Cell Therapies to Treat Solid Tumors at SITC Annual Meeting

On October 5, 2022 Catamaran Bio, Inc., a biotechnology company developing off‑the-shelf NK cell therapies to treat cancer, reported that the company will present preclinical efficacy data for its allogeneic, cryopreserved CAR-NK cell therapies designed to treat solid tumors, engineered using Catamaran’s TAILWINDTM platform (Press release, Catamaran Bio, OCT 5, 2022, View Source [SID1234621744]). The data demonstrate the promise of two of the company’s CAR-NK cell therapies, CAT-248 and CAT-179, for the treatment of solid tumors, and will be presented in two poster presentations at the Society for Immunotherapy in Cancer (SITC) (Free SITC Whitepaper) 37th Annual Meeting, being held in Boston, Massachusetts, November 8-12, 2022.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Details of the poster presentations are as follows:

Title for CAT-248 poster: Engineering CD70-directed CAR-NK cells for the treatment of hematological and solid malignancies

Lead Authors: Branden Moriarity, PhD, Associate Professor, Division of Hematology/ Oncology and Jae-Woong Chang, PhD, Research Associate, University of Minnesota (research agreement sponsored by Catamaran Bio); Eugene Choi, Principal Scientist, Catamaran Bio
Session Date and Time: November 11, 2022, 9:00 a.m. – 8:30 p.m.
Location: Poster Hall
Abstract Number: 392
Title for CAT-179 poster: Allogeneic natural killer cells engineered to express HER2-directed CAR, interleukin-15 and TGFß dominant negative receptor effectively control HER2+ tumors

Lead Author: Finola Moore, PhD, Director, Catamaran Bio
Session Date and Time: November 11, 2022, 9:00 a.m. – 8:30 p.m.
Location: Poster Hall
Abstract Number: 264
Both abstracts will become available online on the SITC (Free SITC Whitepaper) conference website beginning at 8:00 a.m. ET on Monday, November 7, 2022.